Document is current

Article History

Accepted: 24 December 2020

First Online: 31 January 2021

Declarations

:

: RB, MN, MN HP and PL collected data, designed and developed the analysis and wrote and reviewed the manuscript. CG, CJ, FT and JM critically reviewed the analysis of the data and its design and reviewed the manuscript.

: This study was developed by the Portuguese Group of Multiple Myeloma (Grupo Português de Mieloma Múltiplo) and funded by Janssen Portugal.

: Manuel Neves has received honoraria for speaking and/or participation in advisory boards for Janssen, Takeda, Amgen and Celgene. Fernanda Trigo has received honoraria for speaker services from Takeda, Amgen, Celgene and Janssen and for attendance at advisory boards from Takeda, Amgen, Celgene and Janssen. Rui Bergantim has received research grants from APCL/SPH/AMGEN and Celgene and honoraria for speaking and/or participation in advisory boards from Celgene, Janssen, Takeda and Amgen. Cristina João has received a research grant from Takeda and honoraria for speaking and/or participation in advisory boards from Celgene, Janssen, Takeda, AbbVie and Amgen. Paulo Lúcio has received honoraria for speaking and/or participation in advisory boards from Celgene, Janssen, Takeda and Amgen. Mariana Neves and Hugo Pedrosa are employees of IQVIA Solutions Portugal. João Mendes is an employee of Janssen Cilag Farmacêutica, Portugal. Catarina Geraldes has received honoraria from Janssen, Celgene, Amgen, Gilead and Takeda for lectures and participation in advisory boards.

: Data used for this study relied on two main data sources to support the quantification of the burden and cost of MM: the NHS 2016 DRG dataset and the 2013–2018 drug longitudinal retrospective hospital patient dataset of IQVIA Consulting. These datasets are not publicly available and were acquired for the development of this study. Data used are presented in aggregate in this paper. Other public data sources used in the development of this study are disclosed in the reference list.